findmyKOL

Laura Nadeau, MD

Basic profile

Beaumont Health

ORCIDNone on fileNPI
RegionRoyal Oak, MI · MidwestSpecialtyHematology / OncologyFocusOncology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2025Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Laura Nadeau is an Oncology physician affiliated with Beaumont Health. OpenAlex indexes 37 publications with 329 citations (h-index 8).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
37publications

Distinct works indexed by OpenAlex.

329citations

Total citations across indexed works.

8h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
74companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

3577 W 13 Mile Rd
Suite 103
Royal Oak, MI 480736710

Telephone

248-288-4500

Provider last certified this registry record 19 Oct 2020.

View the NPPES registry record

Industry payments

74 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Blood & clotting

    57.2%
    Iron, parenteral preparations49.9%
    Ferric carboxymaltose100%
    Part B, office-administered26 patients
    Erythropoiesis-stimulating Agent7%
    Darbepoetin alfa78%Epoetin alfa22%
    Part B, office-administered15 patients

    + 2 more classes in this area

  • Musculoskeletal

    22.4%
    RANK Ligand Inhibitor22.1%
    Denosumab100%
    Part B, office-administered59 patients
    Bisphosphonate0.2%
    Zoledronic acid100%
    Part B, office-administered20 patients

    + 1 more class in this area

  • Metabolism & gastrointestinal

    11.4%
    Other antiemetics9.1%
    Fosaprepitant100%
    Part B, office-administered13 patients
    Serotonin-3 Receptor Antagonist1.9%
    Palonosetron hcl82%Ondansetron hydrochloride16%Ondansetron Hcl2%
    Part D + Part B34 patients

    + 5 more classes in this area

Where care is delivered (Part B)0.6% facility · 99.4% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”